Available On-Demand
This webinar explores the clinical utility of therapeutic drug monitoring (TDM) for TNFa inhibitors such as adalimumab and infliximab.
Therapeutic drug monitoring (TDM) of TNFa inhibitors is not currently part of the clinical routine, although more than 500,000 patients in the U.S. receive this drug therapy for various diseases. TDM may be useful in preventing adverse events or drug dose adjustment to better treat patients and reduce cost burden.
Key learning objectives
- Explain the clinical utility of TNFa inhibitors in spondyloarthritis and rheumatoid arthritis
- Discuss the importance of drug-level monitoring in patients under TNFa inhibitor therapy
Accreditation statement
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Presenters
Prof. Dr. Hatice Bodur (MD, Ph.D.)
Rheumatology Department,
Ankara Bilkent City Hospital, Ankara, Turkey
Dr. Hatice Bodur graduated from Ankara University Faculty of Medicine and received a postgraduate degree from Ankara Physical Therapy and Rehabilitation Training and Research Hospital. In 1994, she joined Ankara Numune Training and Research Hospital as an associate professor, and in 2013 she assumed the role of professor. In 2019, Dr. Bodur joined Ankara Bilkent City Hospital as a manager of multicenter studies and the biologic-synthetic targeted-DMARD registry in the Turkish League Against Rheumatism.
Dr. Gülsen Yılmaz (MD, Ph.D.)
Medical Biochemistry,
Ankara Bilkent City Hospital, Ankara, Turkey
Dr. Gülsen Yılmaz received her medical degree from Ankara University Faculty of Medicine. In 2013, she served as the head of biochemistry laboratory. In 2014, she served as associate professor at the Ankara Training and Research Hospital. Dr. Yilmaz was a visiting researcher at the Department of Pathology and Laboratory Medicine, University of Wisconsin, U.S., in 2014–2015.
Dr. Yılmaz became a member of the Department of Medical Biochemistry at Ankara Yıldırım Beyazıt University as associate professor in 2014 and professor in 2016. She held positions at Ankara Yıldırım Beyazıt University as chief education coordinator in the Faculty of Medicine, member of the Institute of Health Sciences Executive Board, member of the Ethics Committee, and member of the Medical Laboratory Science Board at the Ministry of Health.
She continues to serve as a corresponding member of the IFCC-Ethics Task Force and an academic member of the Department of Medical Biochemistry at Ankara Yıldırım Beyazıt University and Medical Biochemistry Laboratory at Ankara Bilkent City Hospital.
Dora Wells
Editorial Team
SelectScience